Seres Therapeutics, Inc. (MCRB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MCRB Revenue Growth
Revenue Breakdown (FY 2019)
MCRB's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
MCRB Revenue Analysis (2014–2025)
As of May 8, 2026, Seres Therapeutics, Inc. (MCRB) generated trailing twelve-month (TTM) revenue of $1.1 million. The most recent quarter (Q1 2026) recorded $358,000 in revenue, down 18.3% sequentially.
Looking at the longer-term picture, MCRB's 5-year compound annual growth rate (CAGR) stands at -52.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $144.9 million in 2021.
Revenue diversification analysis shows MCRB's business is primarily driven by License And Service (100%). With over half of revenue concentrated in License And Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NKTR (-43.9% YoY), MIRM (+8.0% YoY), and ARWR (+14.1% YoY). Compare MCRB vs NKTR →
MCRB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MCRBCurrent | $1M | - | -52.7% | -11910.1% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 MIRM | $521M | +8.0% | - | -4.2% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 EVGN | $9M | -26.2% | +62.4% | -255.4% |
MCRB Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $789K | - | $-3,344,000 | -423.8% | $-93,971,000 | -11910.1% |
| 2024 | $0 | - | $-3,532,000 | - | $-121,315,000 | - |
| 2023 | $0 | - | $0 | - | $-195,097,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-179,914,000 | - |
| 2021 | $144.9M | +336.3% | $144.9M | 100.0% | $-64,493,000 | -44.5% |
| 2020 | $33.2M | -3.7% | $-57,355,000 | -172.7% | $-88,130,000 | -265.3% |
| 2019 | $34.5M | +22.1% | $34.5M | 100.0% | $-71,876,000 | -208.3% |
| 2018 | $28.3M | -11.9% | $-67,688,000 | -239.5% | $-100,284,000 | -354.8% |
| 2017 | $32.1M | +47.5% | $-57,355,000 | -178.7% | $-91,395,000 | -284.7% |
| 2016 | $21.8M | - | $-60,223,000 | -276.7% | $-92,839,000 | -426.5% |
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MCRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMCRB — Frequently Asked Questions
Quick answers to the most common questions about buying MCRB stock.
Is MCRB's revenue growth accelerating or slowing?
MCRB TTM revenue: $1M. YoY growth: N/A. 5-year CAGR: -52.7%.
What is MCRB's long-term revenue growth rate?
Seres Therapeutics, Inc.'s 5-year revenue CAGR of -52.7% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MCRB's revenue distributed by segment?
MCRB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.